Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use

Cuomo, Alessandro; Bianchetti, Angelo; Cagnin, Annachiara; Berardis, Domenico De; Fazio, Ignazio Di; Incalzi, Raffaele Antonelli; Marra, Camillo; Neviani, Francesca; Laurenzi, Pier Francesco; Nicoletti, Ferdinando

doi:10.36150/2499-6564-n320

Cited by 10 publications

(13 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Trazodone is a triazolopyridine derivative from the serotonin 5HT2A and 5HT2c receptor antagonist and belongs to the reuptake inhibitors class of antidepressants, approved for major depressive disorder. Additionally, it is commonly used as an off-label medication to treat delirium and insomnia, because it displays a moderately potent antagonist effect over alpha 1A and 2A adrenoreceptors and H1 histaminergic receptors, which is probably related to its sedative effect [ 9 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

Tardive Oromandibular Dystonia Induced by Trazodone: A Clinical Case and Management from the Perspective of the Dental Specialist

Skármeta

Katzmann

Valdes

et al. 2022

Toxins

View full text Add to dashboard Cite

Background: Tardive Oromandibular Dystonia is an iatrogenic drug-induced movement form of extrapyramidal symptoms associated primarily with chronic consumption of dopamine receptor blocking agents. Tardive symptoms attributable to selective serotonin reuptake inhibitors antidepressants are far less prevalent. Clinical Case: The authors will present a clinical case and management, from the dental specialist perspective, of a 55-year-old female patient who developed tardive oromandibular dystonia induced by Trazodone prescribed for sleep insomnia. Conclusions: Trazodone-induced oromandibular dystonia is extremely rare. Early identification and assessment of tardive symptoms are imperative for successful treatment. Trazodone should be prescribed with caution in patients taking other medications with the potential to cause tardive syndromes.

show abstract

Section: Discussionmentioning

confidence: 99%

Tardive Oromandibular Dystonia Induced by Trazodone: A Clinical Case and Management from the Perspective of the Dental Specialist

Skármeta

Katzmann

Valdes

et al. 2022

Toxins

View full text Add to dashboard Cite

show abstract

“…Different studies reported that, in the elderly, even doses between 75 mg and 150 mg per day can be effective in resolving problems of insomnia associated with anxiety/agitation and mood depression [107,108].…”

Section: When Depression Gets Old: Unmet Needs Of Depression In the E...mentioning

confidence: 99%

Treating Depression in Clinical Practice: New Insights on the Multidisciplinary Use of Tradozone

Albert¹,

Tomasetti²,

Marra³

et al. 2023

Preprint

View full text Add to dashboard Cite

Depression is estimated to be a leading contributor to the global mental health-related burden. The determinants of this huge prevalence lie in the fact that depressive symptoms may be comorbid in a wide variety of disorders, thus complicating and exacerbating their clinical pictures. This makes the treatment of depressive symptoms even more difficult since many pharmacological and pharmacokinetic interactions should be considered by physicians approaching the therapy. Hence, depression still represents a challenge for both psychiatrists and the other clinicians, in terms of its high rates of relapse and resistance despite well-established protocols. It is also complicated by the well-known latency in its complete response to current antidepressant treatments. In this context, the search for new strategies in antidepressant treatment is mandatory; even including revising the use of “old” pharmacotherapies by considering their specific features may help to perfecting the treatment of depression, both in its standalone psychiatric manifestation and in the framework of other clinical conditions. The results of a consensus of experts regarding the possible use of trazodone as a valuable strategy for addressing the “real world” unmet needs of depression treatment is herein reported. This is based on the unique characteristics of this drug possibly delivering a rapid antidepressant action as compared to other selective serotonin reuptake inhibitors (SSRIs) as well as on its pharmacodynamic malleability and pharmacokinetic tolerability when used in the milieu of other drugs in treating comorbid depressive symptoms.

show abstract

“…Além disso, a trazodona também pode ser indicada nos casos de dor associada à neuropatia diabética e de outros tipos de dores crônicas [3,4].…”

Section: Introductionunclassified

Avaliação da bioequivalência entre duas formulações de Trazodona – comprimidos revestidos de 100 mg

César¹,

Teixeira²,

Campos³

2023

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

Introdução: A trazodona é um antidepressivo atípico derivado da triazolopiridina, indicado para o tratamento da depressão com ou sem episódios de ansiedade, dor associada à neuropatia diabética e outros tipos de dor crônica. Objetivo: Este estudo teve como objetivo avaliar a bioequivalência entre a formulação teste de Trazodona 100 mg (Sanofi Medley Farmacêutica Ltda) e o produto de referência, Donaren (Apsen Farmacêutica S/A) de acordo com a legislação vigente. Método: Foi realizado um estudo cruzado, aberto, randomizado, de dose única com indivíduos saudáveis de ambos os sexos. A fase clínica foi realizada com 48 indivíduos que receberam os medicamentos em condições de alimentação. A fármaco foi quantificado no plasma por cromatografia líquida acoplada a espectrometria de massas (LC-MS/MS). A avaliação da bioequivalência foi baseada em critérios de aceitação pré-definidos de 80,00 – 125,00% para o intervalo de confiança de 90% para a razão dos produtos teste e referência para os dados log-transformados da área sob a curva (ASC) e da concentração plasmática máxima (Cmax), conforme recomendação da Anvisa. Resultados: As razões geométricas médias (intervalos de confiança de 90%) para Cmax e ASC0-t foram 103,22% (96,13 – 110,84) e 99,06% (94,80 – 103,150), respectivamente. Não houve eventos adversos durante o estudo. Conclusão: As formulações teste e de referência foram consideradas estatisticamente bioequivalentes de acordo com os requisitos regulatórios. A formulação do teste tem sido disponibilizada no mercado local, contribuindo para o acesso da população a medicamentos genéricos de qualidade para o tratamento de transtornos depressivos.

show abstract

Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use

Cited by 10 publications

References 64 publications

Tardive Oromandibular Dystonia Induced by Trazodone: A Clinical Case and Management from the Perspective of the Dental Specialist

Tardive Oromandibular Dystonia Induced by Trazodone: A Clinical Case and Management from the Perspective of the Dental Specialist

Treating Depression in Clinical Practice: New Insights on the Multidisciplinary Use of Tradozone

Avaliação da bioequivalência entre duas formulações de Trazodona – comprimidos revestidos de 100 mg

Contact Info

Product

Resources

About